Division of Neonatology, Department of Pediatrics, University of Illinois at Chicago Medical Center, Chicago, IL 60612., USA.
Neonatology. 2011;99(4):355-66. doi: 10.1159/000326628. Epub 2011 Jun 23.
Since the first successful report of surfactant replacement therapy (SRT) in infants with respiratory distress syndrome (RDS), numerous randomized clinical trials have shown that SRT reduces mortality and morbidity in RDS. Surfactant is now a standard therapy for RDS. However, the use of SRT in the developing world has been extremely slow.
The objective of this paper is to review the published information regarding the usage and barriers encountered in the use of SRT in developing countries.
We reviewed the available literature and also gathered information from countries with a high burden of prematurity and high infant mortality rate regarding replacement therapy and the barriers to use of SRT.
We reviewed the available literature and found that developing countries bear a high burden of prematurity and RDS that contribute to high neonatal and infant mortality rates. Based on the effectiveness of SRT in RDS, surfactant preparations were included in the Essential Drug List of WHO in 2008. However, the use of SRT in developing countries is still limited because of (1) high cost, (2) lack of skilled personnel to administer SRT, and (3) lack of support systems after the SRT. The cost of SRT may exceed the per-capita GNP (300-500 USD) in some countries. Data from India and South Africa suggests that SRT is limited to rescue therapy in babies with potential for better survival, usually >28 weeks' gestation. Recent studies show that infants with RDS respond well to initial continuous positive airway pressure (CPAP) followed by SRT for those who do not respond.
In developing countries, CPAP may be used as the primary mode of management of RDS. SRT may be reserved for non-responders to CPAP. Alternate simpler methods of delivery of surfactant (aerosol technique) are also being explored. There is a need for further studies to develop and assess efficient and less expensive methods of application of CPAP and SRT in developing countries.
自首例呼吸窘迫综合征(RDS)患儿表面活性物质替代疗法(SRT)成功报告以来,众多随机临床试验表明,SRT 可降低 RDS 患儿的死亡率和发病率。目前,表面活性物质已成为 RDS 的标准治疗方法。然而,在发展中国家,SRT 的应用极为缓慢。
本文旨在综述有关发展中国家 SRT 应用的使用情况和障碍的已发表信息。
我们回顾了现有文献,并从早产儿负担重和婴儿死亡率高的国家收集了关于替代治疗和使用 SRT 障碍的信息。
我们查阅了现有文献,发现发展中国家早产儿和 RDS 的负担很重,这导致新生儿和婴儿死亡率居高不下。鉴于 SRT 在 RDS 中的有效性,2008 年世卫组织将表面活性物质制剂纳入了基本药物清单。然而,由于(1)成本高;(2)缺乏施打 SRT 的熟练人员;(3)SRT 后缺乏支持系统,SRT 在发展中国家的应用仍然有限。在一些国家,SRT 的成本可能超过人均国民生产总值(300-500 美元)。来自印度和南非的数据表明,SRT 仅限于那些有更好生存潜力的婴儿的抢救治疗,通常是胎龄>28 周的婴儿。最近的研究表明,对初始持续气道正压通气(CPAP)无反应的 RDS 患儿,CPAP 后给予 SRT 治疗效果良好。
在发展中国家,CPAP 可能作为 RDS 的主要治疗模式。CPAP 无反应者可采用 SRT。还在探索表面活性物质的其他更简单的输送方法(气雾剂技术)。需要进一步研究以开发和评估在发展中国家使用 CPAP 和 SRT 的高效且更经济的方法。